Company / R&D Expense
Amphstar Pharmaceuticals, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$85.8M
FY2025
5-year range
$60.9M / $85.8M
FY2021-FY2025
Trend
+16.1%
vs FY2024
Sector context
#151 of 210
Health Care
What the data says
At $86M, Amphstar Pharmaceuticals, Inc.'s r&d expense ranks #151 of 210 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $42M in FY2016 to $86M in FY2025.
Based on SEC 10-K filings.
$86M in FY2025 with a 5-year CAGR of +5.0%.
Improved from $74M to $86M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +4.7%
- 5-Year CAGR
- +5.0%
- 10-Year CAGR
- -
Sector benchmark
#151 of 210 in Health CareTop 72% of 210This company $85.8M Sector average $644.1M
▼
-86.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.0%, indicating consistent growth.
- In FY2025, r&d expense increased 16.1% year-over-year.
- Ranks #151 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $85.8M | +16.1% |
| FY2024 | $73.9M | +0.2% |
| FY2023 | $73.7M | -1.4% |
| FY2022 | $74.8M | +22.7% |
| FY2021 | $60.9M | -9.4% |
| FY2020 | $67.2M | -2.4% |
| FY2019 | $68.9M | +19.6% |
| FY2018 | $57.6M | +32.3% |
| FY2017 | $43.5M | +4.8% |
| FY2016 | $41.5M | +11.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026